Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TADCLOT: Twice-Daily Clopidogrel vs Ticagrelor in STEMI
NCT06318481Phase 3Completed
- Sponsor
- National Institute of Cardiovascular Diseases
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ticagrelor in ST elevation myocardial infarction (STEMI) (2 arms), sponsored by National Institute of Cardiovascular Diseases. Primary endpoint: Evaluation of efficacy and safety at 30 days. Started Feb 2024; status: completed.
02
Drugs
ticagrelor
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT06318481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06318481.